Efavirenz

證據等級: L5

預測適應症: 3 個

Efavirenz: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) established for the treatment of HIV-1 infection, acting by non-competitively blocking the viral reverse transcriptase enzyme. The TxGNN model predicts it may have activity against Simian Immunodeficiency Virus (SIV) Infection, supported by 1 clinical trial (subsequently withdrawn, enrollment 0) and 16 publications, the majority of which are animal studies conducted in RT-SHIV chimeric macaque models rather than natural SIV disease. The mechanistic bridge to native SIV is structurally weak, placing this prediction in the category of a research model finding rather than an actionable clinical repurposing target.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (NNRTI class antiviral)
Predicted New Indication	Simian Immunodeficiency Virus Infection
TxGNN Prediction Score	99.80%
Evidence Level	L3
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, formal mechanism of action data is not recorded in this evidence pack. Based on known pharmacology and the mechanistic analysis embedded in the retrieved evidence, Efavirenz is an NNRTI that specifically occupies the allosteric non-nucleoside inhibitor binding pocket (NNIBP) on HIV-1 reverse transcriptase (RT), preventing RNA-to-DNA transcription required for viral replication. Its potency is tightly coupled to the shape and electrostatic environment of this pocket — a feature that is characteristic of HIV-1 RT but not conserved across all lentiviruses.

Simian immunodeficiency virus (SIV) is phylogenetically related to HIV-1 but encodes its own RT with key differences at the residues (positions corresponding to Y181, Y188, K103 in HIV-1 RT) that define NNRTI sensitivity. Natural SIV strains are therefore largely resistant to NNRTIs including efavirenz. The published evidence for efavirenz–SIV activity relies almost entirely on RT-SHIV chimeric constructs — experimental viruses where the SIV genomic backbone carries an HIV-1 RT insert — enabling efavirenz to act via its established HIV-1 RT mechanism in macaque hosts. This is a well-validated animal model for studying HIV therapy but represents a research tool application, not a genuine cross-species indication.

In summary, while the TxGNN knowledge graph captures the biological neighborhood linking HIV-1 therapy nodes to SIV research nodes, the mechanistic connection for efavirenz directly treating natural SIV infection is weak. This prediction is best interpreted as the model detecting efavirenz’s utility in HIV primate model systems, not as an independent clinical repurposing target for SIV disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00863668	N/A	Withdrawn	0	Investigated HIV RNA decay kinetics using raltegravir (integrase inhibitor) in HIV-infected patients; references SIV macaque comparisons as contextual background, but is entirely unrelated to efavirenz or direct SIV therapy. Withdrawn before any participants enrolled.

Note: The single retrieved trial was withdrawn with zero enrollment and represents a database ontology mismatch (HIV ↔ SIV cross-tagging). It provides no clinical evidence for efavirenz in SIV infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15328115	2004	Animal Study	Antimicrob Agents Chemother	Directly evaluated efavirenz antiviral activity in RT-SHIV–infected rhesus macaques; demonstrated suppression of the chimeric virus, validating RT-SHIV as an NNRTI testing model
15040537	2004	In Vitro	Antiviral Therapy	Screened 16 antiretrovirals against HIV-2, native SIV (mac251, B670), and SHIV strains; efavirenz showed minimal activity against native SIV (no HIV-1 RT) — a critical negative finding for this indication
15564466	2004	In Vitro	J Virology	In vitro characterization of RT-SHIV chimera susceptibility to NNRTIs including efavirenz; established dose-response parameters for this model system
15919889	2005	Animal Study	J Virology	HAART combination (efavirenz + lamivudine + tenofovir) reduced plasma RT-SHIV viral RNA by >4 logs in rhesus macaques; established the NHP HAART model for AIDS research
19195672	2009	Animal Study	Virology	Characterized vaginal transmission of RT-SHIV in Chinese rhesus macaques with persistent viremia; NNRTI activity assessed in a mucosal exposure context
19889213	2009	Animal Study	Retrovirology	Tracked RT-SHIV subpopulation dynamics under short-course efavirenz monotherapy followed by combination ART in pigtail macaques; resistance dynamics characterized
24777106	2014	Animal Study	Antimicrob Agents Chemother	Enhanced 4–5 drug HAART regimens including efavirenz in RT-SHIV macaques; demonstrated improved early viral decay kinetics compared with standard regimens
35856680	2022	Pharmacology / Imaging	Antimicrob Agents Chemother	Mass spectrometry imaging of efavirenz and 5 other ARVs in NHP spleen tissue; mapped spatial relationship between drug distribution, viral RNA, and fibrosis markers in tissue reservoirs
21084490	2011	Molecular	J Virology	Analyzed SIV/HIV-1 RT genetic diversity before, during, and after ART in macaques; efavirenz monotherapy enabled characterization of resistance mutation emergence
22933296	2012	Molecular	J Virology	Ultrasensitive allele-specific PCR detected pre-existing drug-resistant RT variants in RT-SHIV macaques; quantified efavirenz resistance mutation frequency at baseline

Philippines Market Information

Efavirenz is not currently registered in the Philippines. No active drug license records are available (total registrations: 0).

For reference, Efavirenz is approved by the U.S. FDA (as Sustiva®) and is included in WHO Essential Medicines Lists for HIV/AIDS treatment. A Philippines regulatory application would require submission to the Food and Drug Administration (FDA Philippines) under RA 9711.

Safety Considerations

Please refer to the package insert for complete safety information.

Safety data (key warnings, contraindications, drug interactions) were not available in the current evidence pack. Clinicians should note that efavirenz is associated with CNS adverse effects (vivid dreams, dizziness, neuropsychiatric events), is a CYP3A4 inducer with significant drug-drug interaction potential, and carries teratogenicity warnings — all warranting formal review before any clinical application.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction for efavirenz in SIV infection reflects its established role in RT-SHIV chimeric animal models — powerful research tools for HIV therapy development — rather than a genuine new clinical indication. The critical in vitro evidence (PMID 15040537) confirms that efavirenz has minimal activity against native SIV strains lacking HIV-1 RT, and the only retrieved clinical trial was withdrawn before enrolling any participants. There is no direct path from this prediction to a human health application.

Additional Predicted Indications:

Rank	Indication	Evidence Level	Decision
2	Feline Acquired Immunodeficiency Syndrome (FIV)	L4	Hold
3	Neurodevelopmental Disorder with Ataxic Gait, Absent Speech, and Decreased Cortical White Matter	L5	Hold

The FIV prediction has a biochemical rationale — PMID 38031646 directly compared NNRTIs against FIV-RT vs. HIV-RT — but significant structural divergence at the NNIBP pocket limits efavirenz efficacy against FIV-RT. The neurodevelopmental disorder prediction is purely model-generated (L5) with zero supporting evidence and should not be pursued.

To proceed with any further evaluation, the following would be needed:

Structural crystallography or molecular docking data confirming whether efavirenz can engage native SIV-RT or FIV-RT at the NNIBP
In vitro efficacy data against unmodified SIV strains (excluding RT-SHIV chimeras)
Definition of the intended use context — veterinary application (FIV in cats), primate research tool (SIV models), or translational HIV research — each requiring a separate regulatory and ethical pathway
Philippines FDA registration pathway assessment; no current licenses exist as a starting point
Complete safety profile documentation (MOA, TFDA label warnings, contraindications, DDI profile) to enable any formal safety stage evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.